Table 4. [Benefits and Side Effects of Commonly Used Drugs]. - Endotext

Drugs	Ability to Lower Glucose	Risk of Hypoglycemia	Weight Change	Effect on ASCVD	Effect on CHF	Effect on Renal Disease
2^nd Generation SU	High	Yes	Increase	Neutral	Neutral	Neutral
Metformin	High	No	Neutral- modest weight loss	Potential Benefit	Neutral	Neutral
TZDs	High	No	Increase	Potential Benefit (Pioglitazone)	Increased	Neutral
DPP-4 inhibitors	Intermediate	No	Neutral	Neutral	Potential Increase (saxagliptin and alogliptin)	Neutral
SGLT2 inhibitors	Immediate	No	Decrease	Potential Benefit	Benefit	Benefit- Reduced progression of renal failure
GLP-1 receptor agonists	High	No	Decrease	Benefit	Neutral- Potential Benefit	Benefit- Decreased proteinuria

Drugs

Ability to Lower Glucose

Risk of Hypoglycemia

Weight Change

Effect on ASCVD

Effect on CHF

Effect on Renal Disease

2^nd Generation SU

High

Yes

Increase

Neutral

Metformin

High

Neutral- modest weight loss

Potential Benefit

Neutral

TZDs

High

Increase

Potential Benefit (Pioglitazone)

Increased

Neutral

DPP-4 inhibitors

Intermediate

Neutral

Potential Increase (saxagliptin and alogliptin)

Neutral

SGLT2 inhibitors

Immediate

Decrease

Potential Benefit

Benefit

Benefit-
Reduced progression of renal failure

GLP-1 receptor agonists

High

Decrease

Benefit

Neutral-
Potential Benefit

Benefit-
Decreased proteinuria

Endotext [Internet].

Feingold KR, Anawalt B, Blackman MR, et al., editors.

South Dartmouth (MA): MDText.com, Inc.; 2000-.

This electronic version has been made freely available under a Creative Commons (CC-BY-NC-ND) license. A copy of the license can be viewed at http://creativecommons.org/licenses/by-nc-nd/2.0/.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.